Wheeler Real Estate Investment Trust (WHLR) is expected to report third-quarter 2026 results around mid-November, following its August 6, 2026 release of second-quarter figures. Investors will focus on same-property net operating income (NOI), which grew 7.9% year over year in the first quarter of 2026, as well as funds from operations (FFO) and adjusted FFO (AFFO).

VivoSim Labs is expected to report results for its fiscal second quarter of 2027 (the three months ended September 30, 2026) in early-to-mid November 2026. The company operates in a niche segment of preclinical testing, using 3D human tissue models for liver and intestine toxicity screening.

Pulmatrix (PULM) is expected to report third quarter 2026 results around early November 2026, with a conference call scheduled for November 9, 2026. Limited consensus estimates point to a net loss per share of roughly -$2.00 on revenue near $1.53 million, versus a loss of -$0.24 per share in the year-ago quarter.

Aptevo Therapeutics is expected to report third-quarter 2026 results in early November 2026, with consensus calling for a net loss of roughly $3.72 per share and essentially no revenue. As a clinical-stage biotech, APVO's report will center on cash runway, research and development (R&D) spending, and clinical progress rather than traditional revenue growth.

Curis, Inc. (NASDAQ: CRIS) is scheduled to report its third quarter 2026 financial and operating results on Thursday, November 12, 2026, at 4:00 p.m. ET, followed by a conference call at 4:30 p.m. ET. Wall Street consensus points to a net loss of $2.29 per share on revenue of roughly $1.00 million for the quarter.

Auddia Inc. (NASDAQ: AUUD) reported a GAAP (Generally Accepted Accounting Principles) net loss per share of -$0.71 for its fiscal second quarter of 2026, beating the consensus estimate of -$3.85. Revenue reached roughly $7,580 for the quarter, marking the company's first commercial revenue, driven by an early pilot of its Discovr Radio platform.

Processa Pharmaceuticals reported a net loss of $3.27 million for the second quarter of 2026, narrowing from $3.93 million in the same period a year earlier. Loss per share of $1.19 came in better than analyst consensus estimates, with zero revenue, consistent with the company's clinical-stage status.

Inuvo, Inc. (NYSE American: INUV), an artificial intelligence-driven advertising technology company, is scheduled to report third-quarter 2026 results on Thursday, November 12, 2026, after the market close. Wall Street consensus projects a net loss of approximately $0.19 per share for the quarter ended September 30, 2026, versus a loss of $0.12 per share in the same period a year earlier.

MetaVia is expected to report third-quarter 2026 results in early-to-mid November, with consensus estimates pointing to a net loss per share in a range of roughly $0.73 to $0.94. As a clinical-stage biotech, MetaVia is not expected to report meaningful revenue, so investors will focus on operating expenses, cash runway, and program updates.

Chemomab Therapeutics is expected to report third quarter 2026 financial results before the market opens on November 6, 2026. As a clinical-stage biotechnology company, Chemomab generates no product revenue, so investors will focus on spending, cash runway, and pipeline milestones rather than top-line sales.

Lisata Therapeutics (LSTA), a clinical-stage biotechnology company, is preparing to report its third quarter of fiscal 2026 results, with the release expected in early-to-mid November. As a pre-revenue drug developer, Lisata's report will center on operating expenses, net loss per share, and its cash balance rather than product sales.

PSQ Holdings is scheduled to report third-quarter 2026 results before the U.S. market opens on Friday, November 6, 2026, followed by a conference call at 9:00 a.m. ET. Analysts expect a net loss of roughly $2.13 per share on revenue of about $7.80 million, which would mark revenue growth of approximately 77% from the prior-year period.

Barfresh Food Group (Nasdaq: BRFH) is scheduled to report its third quarter 2026 results on November 16, 2026 , following a difficult second quarter. Analysts expect revenue of about $6.62 million , up roughly 56% from the $4.23 million reported in the prior-year quarter.

Mercer International reported a third-quarter 2026 net loss of $59.2 million, or $0.88 per diluted share, compared with a net loss of $80.8 million, or $1.21 per share, in the same period a year earlier. The company's loss per share of $0.88 came in $0.18 better than the consensus estimate of a $1.06 loss, but revenue of roughly $440.7 million fell short of the approximately $494.6 million analysts had expected.

IN8bio reported a third-quarter 2026 net loss of $4.6 million , or $0.24 per share , compared with a net loss of $3.9 million, or $0.85 per share, a year earlier. The $0.24 per-share loss was narrower than the roughly $0.34 consensus estimate , reflecting a higher weighted-average share count rather than improved profitability.

Cardlytics reported third quarter 2026 revenue of $32.9 million, down 30% year over year and below the consensus estimate of roughly $37 million. Billings, the gross amount billed to advertisers, fell 32% year over year to $57.2 million, reflecting tighter advertiser budgets and earlier bank-partner changes.

InMed Pharmaceuticals (INM) reported a net loss of approximately $2.33 million for the first quarter of fiscal 2027, ended September 30, 2026, compared with roughly $1.73 million in the prior-year period. The company ended the quarter with about $1.09 million in cash and cash equivalents, down from approximately $2.19 million at June 30, 2026.

Quoin Pharmaceuticals reported a net loss of approximately $4.9 million for the third quarter ended September 30, 2026, compared with roughly $3.9 million in the prior-year period. GAAP (Generally Accepted Accounting Principles) earnings per share came in at a loss of $0.97, narrower than the consensus estimate, which ranged around $1.53 to $1.88 per share.

Intensity Therapeutics reported a third-quarter 2026 net loss of $1.09 per share, wider than the roughly $0.94–$0.99 per-share loss analysts had expected. The company's net loss widened to $3.5 million from $2.7 million a year earlier, driven primarily by higher research and development (R&D) spending tied to resumed clinical trial activity.

Neonode Inc. (NEON) is expected to report results for its third quarter of 2026 on Wednesday, November 11, 2026, before the market opens. Analysts are looking for a loss of about $0.09 per share on revenue of roughly $877,000 for the period ended September 30, 2026.